Although some prior studies have demonstrated successful reductions in patients’ blood glucose levels and body weight through digital diabetes programs up to a hemoglobin A1c (HbA1c) reduction of 0.49% [14], many studies were limited by including patients with prediabetes [15], including patients treated with mostly premixed insulin [16], or evaluating user engagement outcomes rather than clinical outcomes [17]. This evidence concerns the gene INS and prediabetes syndrome.